Pharma ETFs In India – 2026

What is a Pharma ETF?

A Pharma ETF (Exchange Traded Fund) is a basket of pharmaceutical and healthcare stocks that trades on a stock exchange, much like a regular company share. Instead of picking individual pharma stocks, an investor can buy a single ETF unit and get exposure to a group of companies engaged in drug manufacturing, formulations, active pharmaceutical ingredients (APIs), and related healthcare businesses.

Most Pharma ETFs in India are passively managed and designed to track a benchmark index, such as the Nifty Pharma Index. The fund holds the same stocks as the index, in broadly the same proportion, so its returns are meant to move closely with the index’s performance, before accounting for expenses and tracking error. Because the fund manager is not actively picking stocks, the running costs of a Pharma ETF are usually lower than those of an actively managed pharma sector mutual fund.

Pharma ETF units are listed and traded on stock exchanges such as the NSE and BSE. This means their price can move throughout the trading day based on demand and supply, in addition to the value of the underlying holdings. To transact in a Pharma ETF, an investor needs a demat account and a trading account, and orders are placed the same way as buying or selling any listed stock.

For investors who want exposure to India’s pharmaceutical and healthcare sector, but do not want to research and select individual companies, a Pharma ETF offers a diversified, relatively low-cost, and easily tradeable route into the sector.

Factors to Consider Before Investing in Pharma ETFs

Before adding a Pharma ETF to a portfolio, it helps to look beyond the fund’s name and check the following factors:

• ETF price and NAV: An ETF’s market price can trade at a slight premium or discount to its Net Asset Value (NAV). Comparing the traded price with the NAV helps investors avoid buying at an inflated premium, particularly in ETFs with lower trading activity.
• Historical returns and performance: Reviewing returns over multiple periods — such as one year, three years, and five years — and across different market cycles gives a more complete picture than looking at a single strong or weak period in isolation.
• Expense ratio: This is the annual fee charged by the fund house, expressed as a percentage of assets. A lower expense ratio means a smaller drag on long-term returns, which matters more the longer the holding period.
• Tracking error: This measures how closely the ETF’s returns follow its benchmark index. A lower tracking error indicates the fund is replicating the index more efficiently.
• Liquidity: Since Pharma ETFs are traded on the exchange, sufficient trading volumes and a narrow bid-ask spread make it easier to buy or sell units at fair prices without significant slippage. Some sector ETFs, including pharma-focused ones, can have thinner trading volumes than broad-market ETFs, so this is worth checking before placing large orders.
• Underlying index: Different Pharma or Healthcare ETFs may track different indices, such as the Nifty Pharma Index or the Nifty Healthcare Index, which can have different constituents and weights. Understanding what the index covers helps confirm the exposure actually matches the investor’s expectations.
• Holdings and sector concentration: Pharma ETFs are concentrated by design, and a small number of large companies can account for a significant share of the index weight. Reviewing the top holdings helps investors understand how concentrated their exposure is to a handful of stocks.
• Fund size (AUM): A reasonably sized fund with adequate assets under management tends to support better liquidity and tighter tracking over time.

How to Invest in Pharma ETFs?

Pharma ETFs are bought and sold on the stock exchange in the same way as listed shares. The broad process is as follows:

• Open a demat and trading account with a broker or investment platform, if one is not already active.
• Log in to the trading platform or app and search for the specific Pharma ETF by its name or NSE/BSE ticker symbol.
• Check the live market price, the ETF’s NAV, and available trading volume before placing an order.
• Place a buy order — either a market order or a limit order specifying the price — for the desired number of units, during regular market trading hours.
• Once the order is executed, the ETF units are credited to the investor’s demat account, similar to shares.
• To exit the investment, the investor can place a sell order for the units at any time the market is open, subject to prevailing prices and liquidity.

A few points worth keeping in mind: since ETFs trade at live market prices, using a limit order rather than a market order can help avoid buying or selling at an unfavourable price during periods of low liquidity. Regular brokerage, transaction charges, and Securities Transaction Tax (STT) apply to ETF trades, as they do to stock trades. Pharma ETFs do not carry a lock-in period, so units can be sold anytime the market is open, unlike tax-saving instruments such as ELSS funds. Investors can also choose to accumulate units gradually over time — for instance through periodic purchases — rather than investing a lump sum at once, depending on their platform’s features and their own investment approach.

Pharma ETF Returns, Taxation and Risks

Historical Returns and Performance

Pharma ETF returns are tied directly to the performance of their underlying index and its constituent stocks, and can vary significantly across market cycles. Since pharma is a cyclical, sentiment-driven sector, returns in any given year can differ meaningfully from longer-term averages, and past performance is not indicative of future results. Investors should check live, up-to-date price, NAV, expense ratio, and return figures on the exchange or fund house website before making any decision.

Taxation

Pharma ETFs that qualify as equity-oriented funds are taxed in line with equity mutual funds and listed shares:

• Short-Term Capital Gains (STCG): Gains on units sold within 12 months of purchase are taxed at 20% under Section 111A of the Income Tax Act.
• Long-Term Capital Gains (LTCG): Gains on units held for more than 12 months are taxed at 12.5% under Section 112A, without indexation benefit, on gains exceeding ₹1.25 lakh in a financial year across all equity assets.
• Securities Transaction Tax (STT) applies on the sale of ETF units, as it does on delivery-based equity trades.

Tax rules can change with future Union Budgets and depend on an individual investor’s overall financial situation, so it is advisable to consult a qualified tax professional or Chartered Accountant before making investment decisions based on tax treatment.

Risks

• Market risk: Like all equity investments, Pharma ETFs are subject to broader stock market volatility and can decline in value along with overall market movements.
• Sector concentration risk: Because the fund invests only in pharma and healthcare stocks, its fortunes are tied closely to a single sector rather than being spread across the economy.
• Regulatory risk: Actions such as USFDA import alerts or warning letters to Indian drug manufacturers, and price control measures from bodies such as the National Pharmaceutical Pricing Authority (NPPA), can affect individual holdings and, in turn, the ETF.
• Currency and export risk: Many Indian pharma companies derive significant revenue from exports, making them sensitive to currency fluctuations and changes in trade or tariff policy in key overseas markets.
• Tracking error and liquidity risk: Deviation from the benchmark index and lower trading volumes in some pharma ETFs can affect the price at which units are bought or sold.